Armin Schueler

5.2k total citations · 2 hit papers
18 papers, 3.8k citations indexed

About

Armin Schueler is a scholar working on Oncology, Otorhinolaryngology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Armin Schueler has authored 18 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 5 papers in Otorhinolaryngology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Armin Schueler's work include Head and Neck Cancer Studies (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Melanoma and MAPK Pathways (3 papers). Armin Schueler is often cited by papers focused on Head and Neck Cancer Studies (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Melanoma and MAPK Pathways (3 papers). Armin Schueler collaborates with scholars based in Germany, Spain and France. Armin Schueler's co-authors include Nadia Amellal, Ricardo Hitt, Jan B. Vermorken, Fernando Rivera, Ricard Mesı́a, Marco Benasso, Sylvie Rottey, Andrzej Kawecki, D. De Raucourt and Didier Cupissol and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Armin Schueler

18 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

2008 2.6k citations Jan B. Vermorken, Ricard Mesı́a et al. New England Journal of Medicine profile →
Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy

2007 734 citations Jan B. Vermorken, José Trigo et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Armin Schueler

Since Specialization

Citations

This map shows the geographic impact of Armin Schueler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Armin Schueler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Armin Schueler more than expected).

Fields of papers citing papers by Armin Schueler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Armin Schueler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Armin Schueler. The network helps show where Armin Schueler may publish in the future.

Co-authorship network of co-authors of Armin Schueler

This figure shows the co-authorship network connecting the top 25 collaborators of Armin Schueler. A scholar is included among the top collaborators of Armin Schueler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Armin Schueler. Armin Schueler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey 2022 ·Therapeutic Innovation & Regulatory Science ·(unknown), Nanco Hefting, (unknown), (unknown), Judith Anzures‐Cabrera, David Wright, Helle Lynggaard, Armin Schueler	15
2	Designing phase I oncology dose escalation using dose–exposure–toxicity models as a complementary approach to model‐based dose–toxicity models 2022 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), (unknown), Alain Munafo, Anja Victor, (unknown), Armin Schueler, Karthik Venkatakrishnan, Pascal Girard, Kosalaram Goteti	7
3	Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover 2020 ·Cancers ·Célèste Lebbé, Caroline Dutriaux, Thierry Lesimple, (unknown), Joseph Kerger, L. Thomas, B. Guillot, Filippo de Braud, Claus Garbe, Jean‐Jacques Grob, Carmen Loquai, Virginia Ferraresi, Caroline Robert, P. Vasey, Robert M. Conry, Richard Isaacs, Enrique Espinosa, Armin Schueler, (unknown), Brigitte Dréno	32
4	Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial 2020 ·Targeted Oncology ·Célèste Lebbé, Antoîne Italiano, Nadine Houédé, Ahmad Awada, Philippe Aftimos, Thierry Lesimple, Monica Dinulescu, Jan H.M. Schellens, Suzanne Leijen, Sylvie Rottey, Vibeke Krüse, Richard Kefford, Éric Raymond, Sandrine Faivre, (unknown), Carlos Gomez‐Roca, Armin Schueler, (unknown), Giorgio Massimini, (unknown)	10
5	Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial 2020 ·Clinical Therapeutics ·Jason D. Lickliter, (unknown), Emmanuelle Vincent, Armin Schueler, (unknown), Corinne Seng Yue, Michael Ståhl, Martin Ullmann, (unknown), Paul Griffin	4
6	Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta^® in healthy subjects: A randomized, double‐blind trial 2020 ·Pharmacology Research & Perspectives ·Chris Wynne, Christian Schwabe, Emmanuelle Vincent, Armin Schueler, (unknown), Martin Ullmann, (unknown), (unknown), Michael Ståhl	4
7	Phase I trial of pimasertib monotherapy in Japanese patients with solid tumors and those with hepatocellular carcinoma 2019 ·Cancer Chemotherapy and Pharmacology ·Kentaro Yamazaki, Toshihiko Doi, Masafumi Ikeda, Takuji Okusaka, Armin Schueler, M. Watanabe, Atsushi Ohtsu	6
8	Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer 2018 ·International Journal of Cancer ·Eric Van Cutsem, Manuel Hidalgo, Jean‐Luc Canon, Teresa Macarulla, I. Bazin, Elena Poddubskaya, Nebojša Manojlović, Dejan Radenković, Chris Verslype, Éric Raymond, Antonio Cubillo, Armin Schueler, (unknown), Pascal Hammel	74
9	Pimasertib (PIM) versus dacarbazine (DTIC) in patients (pts) with cutaneous NRAS melanoma: a controlled, open-label phase II trial with crossover 2016 ·Annals of Oncology ·Célèste Lebbé, Caroline Dutriaux, Thierry Lesimple, Wim H.J. Kruit, Joseph Kerger, L. Thomas, B. Guillot, Filippo de Braud, Claus Garbe, Jean‐Jacques Grob, Carmen Loquai, Virginia Ferraresi, Caroline Robert, P. Vasey, Robert M. Conry, R. Isaacs, Enrique Espinosa, Armin Schueler, (unknown), Brigitte Dréno	13
10	Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study 2011 ·The Lancet Oncology ·Kenneth J. O’Byrne, U. Gatzemeier, Igor Bondarenko, Carlos H. Barrios, (unknown), Uwe M. Martens, Yevhen Hotko, C. Kortsik, Luis Paz‐Ares, Jose R. Pereira, Joachim von Pawel, Rodryg Ramlau, (unknown), Chih‐Teng Yu, Christopher Stroh, Ilhan Celik, Armin Schueler, Robert Pirker	9
11	Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer breakdown → 2008 ·New England Journal of Medicine ·Jan B. Vermorken, Ricard Mesı́a, Fernando Rivera, Éva Remenár, Andrzej Kawecki, Sylvie Rottey, József Erfán, (unknown), (unknown), Didier Cupissol, Frédéric Peyrade, Marco Benasso, Ihor Vynnychenko, D. De Raucourt, Carsten Bokemeyer, Armin Schueler, Nadia Amellal, Ricardo Hitt	2594
12	Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy breakdown → 2007 ·Journal of Clinical Oncology ·Jan B. Vermorken, José Trigo, Ricardo Hitt, P. Koralewski, Eduardo Díaz‐Rubio, Frédéric Rolland, Rainald Knecht, Nadia Amellal, Armin Schueler, José Baselga	734
13	5501 ORAL Cetuximab plus platinum-based therapy first-line in recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety results of a randomized phase III trial (EXTREME) 2007 ·European Journal of Cancer Supplements ·Jan B. Vermorken, Ricardo Hitt, Lionnel Geoffrois, J. Erfán, Andrzej Kawecki, (unknown), Armin Schueler, (unknown), Marco Benasso, H. Kienzer	18
14	Phase I/II Study of Cetuximab in Combination With Cisplatin or Carboplatin and Fluorouracil in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck 2006 ·Journal of Clinical Oncology ·Jean Bourhis, Fernando Rivera, Ricard Mesı́a, Ahmad Awada, L. Geoffrois, Christian Borel, Yves Humblet, Antonio López–Pousa, Ricardo Hitt, (unknown), Lionel Duck, Dominique Rosine, Nadia Amellal, Armin Schueler, A. Harstrick	129
15	Cetuximab in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies 2005 ·Journal of Clinical Oncology ·J. B. Vermorken, Jean Bourhis, José Trigo, M.S. Kies, Xavier León, M. Mueser, Nadia Amellal, Armin Schueler, José Baselga	22
16	Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women 2001 ·Fertility and Sterility ·Katharina Erb, Christine Klipping, Ingrid Duijkers, (unknown), Armin Schueler, Róbert Hermann	31
17	Impact of HBV coinfection on hepatitis C virus infection: analysis of 3054 anti HCV-positive patients 2001 ·Journal of Hepatology ·Heiner Wedemeyer, (unknown), Hans L. Tillmann, Markus Cornberg, Armin Schueler, H. Liermann, Christian Trautwein, M.P. Manns	4
18	Differences between men and women in anxiety early after acute myocardial infarction 2000 ·American Journal of Critical Care ·Kyoung‐Ah Kim, D K Moser, Bonnie J. Garvin, Bárbara Riegel, Lynn V. Doering, Rosemary A. Jadack, S. McKinley, Armin Schueler, (unknown), Ellen McErlean	47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact